

Biomarkers	-0.831 (0.106)***
Sex Characteristics	-0.805 (0.220)***
Vitamin D/blood	-0.688 (0.267)*
Geriatric Assessment	-0.676 (0.172)***
Enzyme-Linked Immunosorbent Assay	-0.669 (0.186)***
Heart Arrest/mortality	-0.663 (0.267)*
Ventricular Dysfunction, Left/diagnostic imaging	-0.650 (0.261)*
Glasgow Coma Scale	-0.595 (0.168)***
Respiration, Artificial/statistics & numerical data	-0.570 (0.207)**
Renal Dialysis/mortality	-0.554 (0.271)*
Immunohistochemistry	-0.523 (0.201)**
Predictive Value of Tests	-0.521 (0.050)***
Stroke/diagnostic imaging	-0.512 (0.197)**
Athletes	-0.510 (0.201)*
Renal Insufficiency, Chronic/blood	-0.508 (0.227)*
Reference Values	-0.507 (0.141)***
ROC Curve	-0.502 (0.082)***
Kidney Failure, Chronic/epidemiology	-0.502 (0.236)*
Risk	-0.498 (0.130)***
Carotid Intima-Media Thickness	-0.495 (0.232)*
Percutaneous Coronary Intervention/adverse effects	-0.481 (0.136)***
Tomography, Optical Coherence/methods	-0.473 (0.111)***
Prognosis	-0.456 (0.038)***
Organ Size	-0.456 (0.183)*
Survivors	-0.454 (0.204)*
Postoperative Complications/blood	-0.451 (0.238)
Anthropometry	-0.447 (0.201)*
Polymorphism, Single Nucleotide	-0.446 (0.158)**
Magnetic Resonance Imaging/methods	-0.445 (0.120)***
Stroke/diagnosis	-0.444 (0.144)**
Kidney Failure, Chronic/mortality	-0.441 (0.223)*
Choroid/pathology	-0.423 (0.218)
Biomarkers/blood	-0.421 (0.057)***
Lung/diagnostic imaging	-0.420 (0.161)**
Neuropsychological Tests	-0.411 (0.135)**
Lactic Acid/blood	-0.410 (0.227)
Atrial Fibrillation/therapy	-0.408 (0.212)
Tomography, Optical Coherence	-0.402 (0.104)***
Aortic Valve/surgery	-0.399 (0.197)*
Up-Regulation	-0.393 (0.195)*
Cardiovascular Diseases/diagnosis	-0.391 (0.168)*
Stroke Volume	-0.390 (0.132)**
Prevalence	-0.386 (0.046)***
Pain, Postoperative/etiology	-0.383 (0.175)*
Hand Strength	-0.382 (0.177)*
Blood Glucose	-0.381 (0.148)**
Cesarean Section/statistics & numerical data	-0.381 (0.188)*
Coronary Artery Bypass/adverse effects	-0.378 (0.196)
Self Report	-0.377 (0.104)***
Aortic Aneurysm, Abdominal/surgery	-0.376 (0.210)

Diabetes Mellitus, Type 1/epidemiology	-0.374 (0.211)
Patient Readmission	-0.373 (0.147)*
Cardiovascular Diseases/physiopathology	-0.373 (0.240)
Preoperative Period	-0.371 (0.146)*
Social Class	-0.369 (0.183)*
Asthma/epidemiology	-0.363 (0.192)
Plaque, Atherosclerotic	-0.363 (0.267)
Biomarkers/metabolism	-0.361 (0.133)**
Pneumonia, Viral/epidemiology	-0.357 (0.450)
Heart Disease Risk Factors	-0.356 (0.197)
COVID-19/mortality	-0.354 (0.166)*
Ultrasonography, Prenatal	-0.352 (0.179)*
Diabetes Mellitus/blood	-0.349 (0.245)
Patient Readmission/statistics & numerical data	-0.347 (0.147)*
Risk Factors	-0.342 (0.027)***
Shock, Septic/mortality	-0.341 (0.239)
Cardiopulmonary Resuscitation	-0.337 (0.182)
Delirium/diagnosis	-0.333 (0.254)
Inflammation	-0.331 (0.184)
Cross-Sectional Studies	-0.331 (0.030)***
Medication Adherence/statistics & numerical data	-0.326 (0.153)*
Glomerular Filtration Rate	-0.325 (0.112)**
Postoperative Complications/physiopathology	-0.325 (0.184)
Pulmonary Veins/surgery	-0.324 (0.215)
Viral Load	-0.321 (0.147)*
Weight Gain	-0.320 (0.182)
Neoplasms/epidemiology	-0.320 (0.163)
Feeding Behavior	-0.318 (0.179)
Heart Valve Prosthesis Implantation/adverse effects	-0.318 (0.226)
Spirometry	-0.317 (0.210)
Depression/epidemiology	-0.310 (0.133)*
Echocardiography/methods	-0.310 (0.186)
Age of Onset	-0.304 (0.161)
Brain Ischemia/epidemiology	-0.303 (0.253)
Heart Failure/blood	-0.298 (0.238)
Neoplasm Grading	-0.297 (0.185)
White People	-0.296 (0.198)
Postoperative Complications/diagnosis	-0.296 (0.132)*
Obesity/epidemiology	-0.295 (0.136)*
Electroencephalography	-0.294 (0.175)
Medicare	-0.293 (0.158)
Geriatric Assessment/methods	-0.292 (0.186)
Incidence	-0.290 (0.040)***
Hypertension/complications	-0.284 (0.148)
Glucose Tolerance Test	-0.284 (0.213)
Hospital Mortality/trends	-0.283 (0.136)*
ST Elevation Myocardial Infarction/diagnosis	-0.280 (0.218)
Adiposity	-0.278 (0.222)
Inflammation/blood	-0.278 (0.207)
Percutaneous Coronary Intervention	-0.277 (0.134)*
Patient Discharge/statistics & numerical data	-0.277 (0.177)

Pregnancy Outcome/epidemiology	-0.276 (0.167)
C-Reactive Protein/metabolism	-0.274 (0.141)
Hospital Mortality	-0.274 (0.059)***
Aortic Valve Stenosis/diagnostic imaging	-0.273 (0.268)
Medication Adherence	-0.272 (0.121)*
Angiotensin-Converting Enzyme Inhibitors/therapeutic use	-0.269 (0.200)
Emergency Medical Services	-0.268 (0.130)*
Stroke/complications	-0.266 (0.140)
Pulmonary Disease, Chronic Obstructive/epidemiology	-0.266 (0.178)
Myocardial Infarction/complications	-0.265 (0.211)
Heart Rate/physiology	-0.262 (0.142)
Myocardial Infarction/mortality	-0.259 (0.154)
Case-Control Studies	-0.258 (0.044)***
Vascular Stiffness	-0.257 (0.270)
Ultrasonography/methods	-0.256 (0.145)
Platelet Aggregation Inhibitors/administration & dosage	-0.255 (0.217)
Analgesics, Opioid/adverse effects	-0.249 (0.186)
Diabetes Mellitus, Type 2/complications	-0.247 (0.097)*
Heart Failure/physiopathology	-0.247 (0.146)
Leukocyte Count	-0.245 (0.183)
Cardiac Surgical Procedures/adverse effects	-0.245 (0.125)*
Inpatients	-0.245 (0.114)*
Heart Defects, Congenital/surgery	-0.244 (0.183)
COVID-19/complications	-0.244 (0.107)*
Lymphocyte Count	-0.242 (0.232)
Spectroscopy, Near-Infrared	-0.240 (0.205)
Practice Patterns, Physicians'	-0.240 (0.150)
Hospitalization	-0.239 (0.058)***
Diabetes Mellitus, Type 2/epidemiology	-0.237 (0.112)*
Critical Care	-0.236 (0.113)*
Emergency Medical Services/methods	-0.236 (0.180)
Anticoagulants/adverse effects	-0.236 (0.140)
Infant, Very Low Birth Weight	-0.234 (0.194)
Independent Living	-0.233 (0.195)
Sepsis/diagnosis	-0.231 (0.175)
Health Status	-0.231 (0.099)*
Proportional Hazards Models	-0.230 (0.065)***
Sedentary Behavior	-0.228 (0.180)
Cognition	-0.227 (0.122)
Myocardial Infarction/etiology	-0.227 (0.187)
Premature Birth/epidemiology	-0.227 (0.187)
Angiogenesis Inhibitors/therapeutic use	-0.227 (0.201)
Tomography, X-Ray Computed	-0.225 (0.082)**
Diabetes Mellitus	-0.225 (0.166)
Stroke Volume/physiology	-0.223 (0.176)
Nutrition Assessment	-0.222 (0.177)
Practice Patterns, Physicians'/statistics & numerical data	-0.220 (0.143)
Ultrasonography	-0.219 (0.081)**
Glomerular Filtration Rate/physiology	-0.216 (0.218)
HIV Infections/complications	-0.215 (0.127)
Renal Dialysis	-0.211 (0.112)

Absorptiometry, Photon	-0.210 (0.194)
Magnetic Resonance Imaging	-0.210 (0.082)*
Anti-Retroviral Agents/therapeutic use	-0.209 (0.210)
Sepsis/blood	-0.209 (0.215)
Gestational Age	-0.206 (0.087)*
Stroke/etiology	-0.206 (0.132)
Morbidity	-0.205 (0.174)
Respiration, Artificial	-0.205 (0.100)*
Coronary Artery Disease/epidemiology	-0.204 (0.178)
Biomarkers/urine	-0.204 (0.189)
C-Reactive Protein/analysis	-0.203 (0.142)
Intensive Care Units	-0.202 (0.064)**
Monitoring, Physiologic/methods	-0.197 (0.170)
Heart Valve Prosthesis Implantation/mortality	-0.190 (0.260)
Fundus Oculi	-0.190 (0.187)
Logistic Models	-0.189 (0.055)***
Anticoagulants/therapeutic use	-0.189 (0.118)
Sex Factors	-0.189 (0.066)**
Cholesterol, HDL/blood	-0.188 (0.223)
Reoperation/statistics & numerical data	-0.186 (0.178)
Biomechanical Phenomena	-0.186 (0.156)
Sex Distribution	-0.186 (0.163)
Blood Pressure	-0.186 (0.101)
Phenotype	-0.183 (0.118)
Electric Impedance	-0.183 (0.192)
Peripheral Arterial Disease/diagnosis	-0.179 (0.210)
Postoperative Complications/epidemiology	-0.178 (0.068)**
Coronary Artery Disease/physiopathology	-0.178 (0.186)
Biopsy	-0.178 (0.114)
Hypertension/diagnosis	-0.177 (0.183)
Postpartum Period	-0.176 (0.179)
Peptide Fragments/blood	-0.176 (0.247)
Biomarkers/analysis	-0.176 (0.145)
Out-of-Hospital Cardiac Arrest/therapy	-0.175 (0.162)
Diabetes Mellitus, Type 1/blood	-0.174 (0.201)
Laparoscopy/adverse effects	-0.173 (0.168)
Emergency Service, Hospital/statistics & numerical data	-0.173 (0.097)
COVID-19/diagnosis	-0.172 (0.143)
Cohort Studies	-0.171 (0.029)***
Fluorescein Angiography	-0.171 (0.163)
Blood Glucose/analysis	-0.169 (0.130)
Electrocardiography	-0.169 (0.104)
Computed Tomography Angiography	-0.168 (0.167)
Kidney Failure, Chronic/complications	-0.168 (0.193)
Mortality/trends	-0.168 (0.170)
Myocardial Infarction/epidemiology	-0.167 (0.152)
Disease Progression	-0.167 (0.056)**
Child Development	-0.165 (0.195)
Pulmonary Disease, Chronic Obstructive/physiopathology	-0.165 (0.164)
ST Elevation Myocardial Infarction/mortality	-0.163 (0.246)
Fluorescein Angiography/methods	-0.162 (0.203)

Microbial Sensitivity Tests	-0.160 (0.155)
Macula Lutea/pathology	-0.160 (0.208)
SARS-CoV-2	-0.158 (0.070)*
Longitudinal Studies	-0.157 (0.043)***
Creatinine/blood	-0.155 (0.147)
Postmenopause	-0.155 (0.201)
Cardiac Surgical Procedures	-0.154 (0.156)
Patient Acceptance of Health Care	-0.149 (0.161)
Polypharmacy	-0.148 (0.192)
Frail Elderly	-0.147 (0.193)
Cardiopulmonary Resuscitation/methods	-0.145 (0.182)
Atrial Fibrillation/epidemiology	-0.145 (0.145)
Drug-Eluting Stents	-0.143 (0.181)
Patient Reported Outcome Measures	-0.141 (0.108)
Registries	-0.139 (0.046)**
Acute Kidney Injury/mortality	-0.139 (0.203)
Databases, Factual	-0.138 (0.071)
Depression/etiology	-0.138 (0.196)
Mortality	-0.137 (0.144)
Intensive Care Units, Pediatric	-0.136 (0.153)
Atrial Fibrillation/mortality	-0.135 (0.201)
Acute Kidney Injury/diagnosis	-0.135 (0.165)
Kidney Failure, Chronic/diagnosis	-0.133 (0.230)
Transcatheter Aortic Valve Replacement/adverse effects	-0.132 (0.218)
Diabetes Mellitus, Type 1/complications	-0.132 (0.178)
Sepsis/mortality	-0.131 (0.173)
Oxygen	-0.131 (0.161)
Health Care Costs	-0.128 (0.137)
Pulmonary Disease, Chronic Obstructive/complications	-0.128 (0.187)
Aortic Valve Stenosis/physiopathology	-0.128 (0.313)
Heart Failure/diagnosis	-0.126 (0.142)
Multivariate Analysis	-0.126 (0.061)*
Insulin Resistance	-0.126 (0.153)
Critical Illness	-0.125 (0.084)
Depression/psychology	-0.125 (0.155)
Perception	-0.124 (0.174)
Disability Evaluation	-0.122 (0.098)
Antirheumatic Agents/therapeutic use	-0.121 (0.140)
Platelet Aggregation Inhibitors/therapeutic use	-0.121 (0.148)
Patient Admission	-0.121 (0.151)
Syndrome	-0.121 (0.185)
Betacoronavirus	-0.118 (0.223)
Acute Coronary Syndrome/epidemiology	-0.118 (0.239)
Treatment Failure	-0.118 (0.118)
Hospitalization/statistics & numerical data	-0.116 (0.078)
Insulin/therapeutic use	-0.116 (0.173)
Anti-Bacterial Agents/adverse effects	-0.116 (0.177)
Severity of Illness Index	-0.115 (0.040)**
Renal Insufficiency, Chronic/epidemiology	-0.114 (0.156)
Walking	-0.114 (0.168)
Acute Disease	-0.113 (0.083)

Regression Analysis	-0.113 (0.097)
HIV Infections/epidemiology	-0.112 (0.127)
Heart Ventricles/physiopathology	-0.110 (0.237)
Respiration, Artificial/adverse effects	-0.109 (0.179)
Cardiovascular Diseases/etiology	-0.109 (0.153)
Birth Weight	-0.108 (0.132)
Echocardiography	-0.106 (0.100)
Europe/epidemiology	-0.106 (0.151)
Aging	-0.105 (0.194)
Atrial Fibrillation/surgery	-0.104 (0.173)
Crohn Disease/drug therapy	-0.104 (0.161)
Patient Discharge	-0.103 (0.099)
Sleep	-0.103 (0.140)
Linear Models	-0.100 (0.087)
Postoperative Complications/etiology	-0.100 (0.074)
Parity	-0.099 (0.191)
Analysis of Variance	-0.098 (0.135)
Lung Neoplasms/drug therapy	-0.097 (0.259)
Sepsis/epidemiology	-0.097 (0.178)
Ventricular Function, Left/physiology	-0.095 (0.203)
Ethnicity	-0.095 (0.167)
Kidney Transplantation/adverse effects	-0.094 (0.150)
Adolescent	-0.094 (0.033)**
Injury Severity Score	-0.093 (0.134)
Hemorrhage/epidemiology	-0.092 (0.181)
Retina/pathology	-0.091 (0.199)
Bone Density	-0.090 (0.171)
Out-of-Hospital Cardiac Arrest/mortality	-0.089 (0.188)
Exercise	-0.089 (0.101)
Cardiovascular Diseases/epidemiology	-0.088 (0.113)
Antineoplastic Agents/therapeutic use	-0.087 (0.132)
Body Mass Index	-0.087 (0.061)
Atrial Fibrillation/drug therapy	-0.087 (0.156)
Critical Illness/mortality	-0.086 (0.167)
Critical Care/methods	-0.085 (0.154)
Kidney Failure, Chronic/blood	-0.084 (0.249)
Cerebrovascular Circulation	-0.084 (0.186)
Activities of Daily Living	-0.082 (0.099)
Nerve Fibers/pathology	-0.080 (0.298)
Arthritis, Rheumatoid/drug therapy	-0.079 (0.152)
Depression/diagnosis	-0.078 (0.177)
Diabetes Mellitus/epidemiology	-0.077 (0.127)
Emergency Medical Services/statistics & numerical data	-0.076 (0.190)
Percutaneous Coronary Intervention/mortality	-0.075 (0.175)
Survival Analysis	-0.074 (0.079)
Fibrinolytic Agents/therapeutic use	-0.074 (0.188)
Female	-0.074 (0.032)*
Health Surveys	-0.071 (0.185)
Age Factors	-0.070 (0.051)
Stroke/physiopathology	-0.070 (0.160)
Mental Health	-0.069 (0.136)

Genetic Predisposition to Disease	-0.069 (0.159)
Respiratory Function Tests	-0.068 (0.163)
Surveys and Questionnaires	-0.064 (0.041)
Postoperative Period	-0.062 (0.088)
Blood Pressure/physiology	-0.062 (0.126)
Exercise/physiology	-0.061 (0.144)
Prostatic Neoplasms/pathology	-0.061 (0.202)
Pregnancy Outcome	-0.060 (0.116)
Heart Failure/epidemiology	-0.060 (0.145)
Physicians	-0.060 (0.161)
Hypoglycemic Agents/administration & dosage	-0.059 (0.171)
Pulmonary Disease, Chronic Obstructive/diagnosis	-0.059 (0.180)
Population Surveillance	-0.059 (0.199)
Odds Ratio	-0.059 (0.074)
Delivery of Health Care	-0.056 (0.154)
Stroke/epidemiology	-0.055 (0.119)
Socioeconomic Factors	-0.054 (0.085)
Comorbidity	-0.054 (0.058)
Kaplan-Meier Estimate	-0.053 (0.068)
Coronary Angiography	-0.053 (0.112)
Percutaneous Coronary Intervention/methods	-0.052 (0.165)
Overweight/epidemiology	-0.051 (0.211)
Social Support	-0.051 (0.184)
Renal Insufficiency, Chronic/physiopathology	-0.051 (0.184)
Anesthesia, General	-0.051 (0.165)
Heart Ventricles/diagnostic imaging	-0.051 (0.215)
Pregnancy	-0.050 (0.053)
Waist Circumference	-0.048 (0.201)
Propensity Score	-0.046 (0.075)
Wounds and Injuries/therapy	-0.046 (0.183)
Brain/diagnostic imaging	-0.045 (0.154)
Fibrosis	-0.045 (0.199)
Acute Kidney Injury/etiology	-0.044 (0.152)
Blood Flow Velocity	-0.043 (0.180)
Liver Cirrhosis/complications	-0.043 (0.159)
Metabolic Syndrome/epidemiology	-0.042 (0.206)
Health Behavior	-0.041 (0.178)
Infant	-0.041 (0.048)
Guideline Adherence/statistics & numerical data	-0.040 (0.180)
Defibrillators, Implantable	-0.039 (0.179)
Disease-Free Survival	-0.039 (0.096)
Liver/pathology	-0.037 (0.187)
Heart Failure/etiology	-0.037 (0.222)
Heart Failure/mortality	-0.037 (0.139)
Neoplasms/complications	-0.037 (0.143)
Platelet Count	-0.036 (0.177)
APACHE	-0.036 (0.153)
Aged, 80 and over	-0.036 (0.027)
Intensive Care Units/organization & administration	-0.035 (0.199)
Trauma Centers	-0.035 (0.162)
Aortic Valve Stenosis/surgery	-0.032 (0.208)

Reproducibility of Results	-0.032 (0.064)
Tomography, X-Ray Computed/methods	-0.031 (0.130)
Aged	-0.030 (0.024)
Pain Measurement/methods	-0.030 (0.159)
Acute Coronary Syndrome/mortality	-0.030 (0.211)
Cardiovascular Diseases/mortality	-0.029 (0.154)
Tumor Necrosis Factor-alpha/antagonists & inhibitors	-0.029 (0.157)
Quality of Health Care	-0.027 (0.158)
Physician-Patient Relations	-0.026 (0.172)
Pregnancy Complications/epidemiology	-0.026 (0.172)
Psychiatric Status Rating Scales	-0.025 (0.147)
Brain Ischemia/diagnosis	-0.023 (0.224)
Primary Health Care	-0.023 (0.110)
Cesarean Section	-0.022 (0.151)
Mutation	-0.022 (0.121)
Acute Kidney Injury/epidemiology	-0.021 (0.161)
Adrenergic beta-Antagonists/therapeutic use	-0.021 (0.202)
Age Distribution	-0.019 (0.155)
Glycated Hemoglobin/metabolism	-0.019 (0.143)
Inflammatory Bowel Diseases/drug therapy	-0.017 (0.174)
Adalimumab/therapeutic use	-0.017 (0.201)
Malnutrition/epidemiology	-0.015 (0.207)
Administration, Inhalation	-0.015 (0.182)
Critical Illness/therapy	-0.014 (0.124)
Heart Failure/complications	-0.013 (0.156)
Health Status Disparities	-0.013 (0.195)
Male	-0.013 (0.030)
Lung/physiopathology	-0.012 (0.154)
Blood Vessel Prosthesis Implantation/adverse effects	-0.011 (0.196)
Patient Selection	-0.010 (0.121)
Hospitalization/economics	-0.010 (0.180)
Aortic Valve/physiopathology	-0.010 (0.336)
Retrospective Studies	-0.008 (0.021)
Polysomnography	-0.006 (0.164)
Diabetes Mellitus, Type 2/blood	-0.005 (0.131)
Nutritional Status	-0.005 (0.116)
Anxiety/etiology	-0.003 (0.213)
Adult	-0.003 (0.021)
Triglycerides/blood	-0.002 (0.186)
Infant, Newborn	-0.002 (0.048)
Colorectal Neoplasms/surgery	-0.002 (0.170)
Organ Dysfunction Scores	-0.001 (0.176)
Anxiety/psychology	-0.000 (0.169)
Diabetes Mellitus, Type 2/physiopathology	-0.000 (0.186)
Child, Preschool	0.000 (0.051)
Vital Capacity	0.002 (0.222)
Blood Transfusion	0.003 (0.162)
Patient Admission/statistics & numerical data	0.003 (0.167)
Acute Coronary Syndrome/therapy	0.003 (0.197)
Endovascular Procedures/adverse effects	0.004 (0.170)
Risk Assessment	0.005 (0.047)



Hemorrhage/etiology	0.006 (0.166)
Neoplasm Staging	0.006 (0.089)
Asthma/drug therapy	0.008 (0.165)
Infliximab/therapeutic use	0.009 (0.191)
Hospitalization/trends	0.009 (0.161)
Exercise Test	0.010 (0.148)
Antihypertensive Agents/therapeutic use	0.011 (0.155)
Atrial Fibrillation/complications	0.011 (0.147)
Anxiety/epidemiology	0.012 (0.172)
Coronary Artery Disease/therapy	0.014 (0.167)
Adrenal Cortex Hormones/therapeutic use	0.015 (0.145)
COVID-19 Drug Treatment	0.015 (0.167)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use	0.016 (0.138)
Hypoglycemic Agents/therapeutic use	0.017 (0.132)
Emergency Service, Hospital	0.018 (0.068)
Blood Glucose/metabolism	0.019 (0.116)
Anticoagulants/administration & dosage	0.019 (0.155)
Pain	0.022 (0.135)
Stroke/drug therapy	0.023 (0.171)
Acute Coronary Syndrome/diagnosis	0.023 (0.186)
Myocardial Infarction/therapy	0.024 (0.172)
Emergencies	0.025 (0.184)
Risk Assessment/methods	0.027 (0.098)
Coronary Artery Disease/diagnosis	0.027 (0.164)
Time Factors	0.027 (0.032)
Middle Aged	0.028 (0.025)
Neoplasms/therapy	0.029 (0.160)
Asymptomatic Diseases	0.029 (0.213)
Pilot Projects	0.030 (0.062)
Analgesics, Opioid/therapeutic use	0.032 (0.124)
Prospective Studies	0.033 (0.020)
Blood Glucose/drug effects	0.035 (0.206)
Renal Insufficiency, Chronic/mortality	0.036 (0.227)
Cost of Illness	0.036 (0.124)
Chronic Disease	0.037 (0.077)
Coronary Artery Disease/surgery	0.037 (0.155)
Endovascular Procedures/mortality	0.038 (0.226)
Obesity/complications	0.038 (0.110)
Catheter Ablation/adverse effects	0.039 (0.185)
Retinal Ganglion Cells/pathology	0.040 (0.293)
Colorectal Neoplasms/pathology	0.041 (0.149)
Body Composition	0.041 (0.156)
Coronary Artery Disease/complications	0.042 (0.186)
Infant, Premature	0.042 (0.103)
Cause of Death	0.043 (0.106)
Kidney Transplantation	0.044 (0.155)
ST Elevation Myocardial Infarction/therapy	0.046 (0.210)
Diabetes Mellitus, Type 2/therapy	0.050 (0.190)
Chemotherapy, Adjuvant	0.050 (0.176)
Pain Measurement	0.051 (0.089)
Heart Rate	0.052 (0.130)

Survival Rate/trends	0.053 (0.108)
Diagnosis, Differential	0.053 (0.135)
Obesity, Morbid/surgery	0.054 (0.144)
COVID-19/therapy	0.056 (0.129)
Registries/statistics & numerical data	0.057 (0.170)
Breast Neoplasms/pathology	0.058 (0.139)
Black or African American	0.058 (0.225)
Renal Insufficiency, Chronic/complications	0.060 (0.137)
Arthritis, Rheumatoid/diagnosis	0.060 (0.190)
Contrast Media	0.061 (0.187)
Neoplasms/drug therapy	0.062 (0.145)
Renal Insufficiency, Chronic/therapy	0.064 (0.173)
Genotype	0.065 (0.109)
Sepsis/complications	0.066 (0.179)
Academic Medical Centers	0.074 (0.168)
Intensive Care Units/statistics & numerical data	0.074 (0.114)
Radiography	0.074 (0.128)
Coronary Artery Disease/diagnostic imaging	0.074 (0.145)
Mental Disorders/epidemiology	0.076 (0.176)
Coronary Artery Disease/blood	0.077 (0.198)
Myocardial Infarction/blood	0.080 (0.234)
Smoking/epidemiology	0.080 (0.152)
Seasons	0.081 (0.139)
Renal Dialysis/adverse effects	0.081 (0.148)
Cross Infection/epidemiology	0.082 (0.153)
Atrial Fibrillation/physiopathology	0.084 (0.162)
HIV Infections/virology	0.087 (0.197)
Hospitals	0.087 (0.079)
Renal Insufficiency, Chronic/diagnosis	0.087 (0.181)
Child	0.088 (0.038)*
Intraocular Pressure	0.089 (0.145)
Intubation, Intratracheal	0.092 (0.180)
Anti-Bacterial Agents/therapeutic use	0.093 (0.072)
Postoperative Complications/mortality	0.094 (0.134)
Young Adult	0.094 (0.031)**
Diabetes Mellitus, Type 2/mortality	0.096 (0.214)
Respiration, Artificial/methods	0.097 (0.162)
Action Potentials	0.098 (0.238)
Tertiary Care Centers	0.098 (0.074)
Stroke/therapy	0.099 (0.139)
Sensitivity and Specificity	0.100 (0.073)
Follow-Up Studies	0.101 (0.031)**
Intensive Care Units, Neonatal	0.102 (0.142)
Postoperative Complications	0.103 (0.110)
Bariatric Surgery	0.105 (0.182)
Hemorrhage/chemically induced	0.106 (0.145)
Practice Guidelines as Topic	0.107 (0.111)
Glycated Hemoglobin/analysis	0.109 (0.125)
Survival Rate	0.109 (0.073)
Postoperative Complications/therapy	0.110 (0.188)
Echocardiography, Doppler	0.111 (0.196)

Colonoscopy	0.112 (0.168)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use	0.112 (0.121)
Kidney Failure, Chronic/therapy	0.112 (0.146)
Ventricular Dysfunction, Left/physiopathology	0.112 (0.225)
Reoperation	0.113 (0.122)
Laparoscopy	0.115 (0.133)
Length of Stay/statistics & numerical data	0.117 (0.083)
Stroke Rehabilitation	0.118 (0.191)
Graft Survival	0.118 (0.160)
Rural Population	0.119 (0.169)
Early Diagnosis	0.121 (0.137)
Endovascular Procedures/instrumentation	0.124 (0.215)
Coronary Angiography/methods	0.124 (0.175)
Hypertension/physiopathology	0.127 (0.175)
Delirium/epidemiology	0.128 (0.229)
Atrial Fibrillation/diagnosis	0.128 (0.139)
Statistics, Nonparametric	0.129 (0.130)
Elective Surgical Procedures	0.131 (0.154)
Obesity/diagnosis	0.132 (0.211)
Drug-Related Side Effects and Adverse Reactions/epidemiology	0.134 (0.165)
Patient Compliance	0.134 (0.150)
Stroke/mortality	0.134 (0.155)
COVID-19/epidemiology	0.135 (0.076)
Ventricular Function, Left	0.135 (0.140)
Neoplasm Recurrence, Local	0.136 (0.166)
HIV Infections/drug therapy	0.137 (0.132)
Europe	0.138 (0.123)
Percutaneous Coronary Intervention/instrumentation	0.139 (0.203)
Length of Stay	0.141 (0.064)*
Chi-Square Distribution	0.145 (0.095)
Anti-Bacterial Agents/administration & dosage	0.145 (0.134)
Palliative Care	0.147 (0.169)
Recurrence	0.150 (0.063)*
Range of Motion, Articular	0.150 (0.155)
Diabetes Mellitus, Type 2/diagnosis	0.153 (0.145)
Breast Neoplasms/drug therapy	0.153 (0.146)
Asian People	0.155 (0.150)
Diet	0.157 (0.144)
COVID-19	0.161 (0.083)
Heart Failure/therapy	0.163 (0.132)
Coronary Artery Disease/mortality	0.164 (0.162)
Lumbar Vertebrae/surgery	0.165 (0.155)
Educational Status	0.167 (0.143)
Heart Failure/drug therapy	0.167 (0.170)
Respiratory Distress Syndrome/therapy	0.171 (0.166)
CD4 Lymphocyte Count	0.172 (0.166)
Aortic Valve/diagnostic imaging	0.172 (0.276)
Cause of Death/trends	0.173 (0.224)
Aortic Valve Stenosis/mortality	0.174 (0.236)
Administration, Oral	0.177 (0.100)
Humans	0.179 (0.196)

Health Personnel	0.182 (0.144)
Platelet Aggregation Inhibitors/adverse effects	0.182 (0.188)
Pandemics	0.185 (0.079)*
Hemodynamics	0.187 (0.108)
Communicable Disease Control	0.188 (0.163)
Breast Neoplasms/surgery	0.190 (0.160)
Intubation, Intratracheal/methods	0.191 (0.165)
Hip Fractures/surgery	0.191 (0.159)
Referral and Consultation	0.195 (0.109)
Surgical Wound Infection/epidemiology	0.196 (0.171)
Observer Variation	0.196 (0.163)
Heart Arrest/therapy	0.197 (0.183)
Anticonvulsants/therapeutic use	0.197 (0.176)
Hypertension/epidemiology	0.197 (0.123)
Hospitals, University	0.198 (0.114)
Patient Acceptance of Health Care/statistics & numerical data	0.199 (0.155)
Immunosuppressive Agents/therapeutic use	0.200 (0.116)
Oxygen/blood	0.201 (0.145)
Coronavirus Infections/epidemiology	0.204 (0.470)
Hemodynamics/physiology	0.205 (0.181)
Outpatients	0.208 (0.134)
Cardiac Catheterization/adverse effects	0.208 (0.189)
Healthy Volunteers	0.210 (0.117)
Physical Therapy Modalities	0.213 (0.160)
Pulse Wave Analysis	0.214 (0.225)
Body Weight	0.215 (0.124)
Visual Acuity	0.216 (0.087)*
Endovascular Procedures/methods	0.226 (0.174)
Antiviral Agents/therapeutic use	0.230 (0.122)
Anti-HIV Agents/therapeutic use	0.231 (0.169)
Energy Intake	0.231 (0.164)
Acute Kidney Injury/therapy	0.234 (0.167)
Decision Making	0.235 (0.149)
Diabetes Mellitus, Type 2/drug therapy	0.241 (0.122)*
Myocardial Infarction/diagnosis	0.241 (0.164)
Quality of Life/psychology	0.242 (0.117)*
Breast Feeding	0.247 (0.177)
Pain/etiology	0.249 (0.144)
Acute Kidney Injury/blood	0.252 (0.229)
Protective Factors	0.252 (0.167)
Area Under Curve	0.253 (0.126)*
Hypertension/drug therapy	0.254 (0.162)
Clinical Decision-Making	0.255 (0.136)
Diabetes Mellitus/diagnosis	0.255 (0.194)
Smoking/adverse effects	0.255 (0.155)
Hemoglobins/analysis	0.256 (0.168)
Drug Administration Schedule	0.256 (0.095)**
Drug Therapy, Combination	0.257 (0.076)***
Visual Acuity/physiology	0.263 (0.122)*
Neoplasm Recurrence, Local/pathology	0.263 (0.154)
Immunosuppressive Agents/adverse effects	0.264 (0.163)

Hospitals, Teaching	0.266 (0.143)
Triage	0.270 (0.162)
Preoperative Care/methods	0.270 (0.174)
Attitude of Health Personnel	0.271 (0.139)
Outcome Assessment, Health Care	0.275 (0.083) <sup>***</sup>
Combined Modality Therapy	0.277 (0.117) <sup>*</sup>
Hypoglycemic Agents/adverse effects	0.279 (0.167)
Respiratory Insufficiency/therapy	0.280 (0.154)
Pulmonary Disease, Chronic Obstructive/drug therapy	0.280 (0.205)
Carcinoma, Non-Small-Cell Lung/drug therapy	0.282 (0.298)
Recovery of Function	0.285 (0.082) <sup>***</sup>
Infusions, Intravenous	0.287 (0.147)
Health Knowledge, Attitudes, Practice	0.287 (0.111) <sup>**</sup>
Prosthesis Design	0.287 (0.108) <sup>**</sup>
Laparoscopy/methods	0.292 (0.126) <sup>*</sup>
Stroke/prevention & control	0.297 (0.160)
Antineoplastic Agents/adverse effects	0.297 (0.152)
Brain Ischemia/complications	0.297 (0.206)
Electronic Health Records	0.300 (0.129) <sup>*</sup>
Lung Neoplasms/pathology	0.301 (0.214)
Dose-Response Relationship, Drug	0.304 (0.096) <sup>**</sup>
Interleukin-6/blood	0.307 (0.185)
Communication	0.308 (0.136) <sup>*</sup>
Time-to-Treatment	0.310 (0.118) <sup>**</sup>
Tertiary Care Centers/statistics & numerical data	0.310 (0.170)
Heart Valve Prosthesis	0.315 (0.185)
Lumbar Vertebrae/diagnostic imaging	0.315 (0.175)
Operative Time	0.317 (0.118) <sup>**</sup>
Cholesterol, LDL/blood	0.317 (0.184)
Vitamin D/analogs & derivatives	0.322 (0.279)
Internship and Residency	0.323 (0.156) <sup>*</sup>
Antibodies, Monoclonal, Humanized/therapeutic use	0.330 (0.130) <sup>*</sup>
Natriuretic Peptide, Brain/blood	0.331 (0.219)
Vascular Patency	0.342 (0.163) <sup>*</sup>
Coronary Vessels/diagnostic imaging	0.342 (0.162) <sup>*</sup>
Hemoglobins/metabolism	0.342 (0.176)
Progression-Free Survival	0.347 (0.144) <sup>*</sup>
Animals	0.351 (0.095) <sup>***</sup>
Analgesics, Opioid/administration & dosage	0.352 (0.165) <sup>*</sup>
Stents	0.355 (0.112) <sup>**</sup>
Outcome and Process Assessment, Health Care	0.356 (0.162) <sup>*</sup>
Remission Induction	0.360 (0.115) <sup>**</sup>
Obesity/physiopathology	0.361 (0.178) <sup>*</sup>
Cardiac Surgical Procedures/methods	0.361 (0.181) <sup>*</sup>
Quality of Life	0.362 (0.041) <sup>***</sup>
Weight Loss	0.370 (0.124) <sup>**</sup>
Pain Management/methods	0.373 (0.150) <sup>*</sup>
Decision Support Techniques	0.381 (0.143) <sup>**</sup>
Glucocorticoids/therapeutic use	0.382 (0.148) <sup>**</sup>
Forced Expiratory Volume	0.389 (0.173) <sup>*</sup>
Pain, Postoperative/drug therapy	0.392 (0.155) <sup>*</sup>

Vaccination	0.394 (0.144)**
Administration, Intravenous	0.399 (0.140)**
Patient Satisfaction	0.401 (0.090)***
Kidney/physiopathology	0.402 (0.152)**
Point-of-Care Systems	0.403 (0.169)*
Anti-Bacterial Agents/pharmacology	0.411 (0.164)*
Emergency Service, Hospital/organization & administration	0.413 (0.154)**
Disease Management	0.419 (0.144)**
Postoperative Complications/surgery	0.437 (0.169)**
Life Style	0.439 (0.141)**
Coronary Artery Bypass/mortality	0.440 (0.245)
Antineoplastic Combined Chemotherapy Protocols/adverse effects	0.443 (0.160)**
Guideline Adherence	0.444 (0.144)**
Dietary Supplements	0.444 (0.170)**
Cardiovascular Diseases/blood	0.462 (0.180)*
Clinical Competence	0.471 (0.111)***
Patient Safety	0.475 (0.132)***
Intraocular Pressure/physiology	0.475 (0.163)**
Postoperative Complications/prevention & control	0.483 (0.119)***
Blood Pressure/drug effects	0.486 (0.173)**
Catheter Ablation/methods	0.489 (0.181)**
Diabetes Mellitus, Type 1/drug therapy	0.489 (0.187)**
Cardiovascular Diseases/prevention & control	0.491 (0.160)**
Treatment Outcome	0.495 (0.024)***
Lipids/blood	0.501 (0.167)**
Colitis, Ulcerative/drug therapy	0.508 (0.173)**
Pulmonary Disease, Chronic Obstructive/therapy	0.542 (0.195)**
Inflammation Mediators/blood	0.557 (0.210)**
COVID-19/prevention & control	0.580 (0.111)***
Algorithms	0.605 (0.106)***
Intravitreal Injections	0.607 (0.147)***
Antibodies, Monoclonal/therapeutic use	0.634 (0.170)***
Feasibility Studies	0.654 (0.084)***
Hepatitis C, Chronic/drug therapy	0.679 (0.173)***
Equipment Design	0.682 (0.113)***
Ultrasonography, Interventional	0.777 (0.161)***
Quality Improvement	0.946 (0.126)***
Drug Combinations	0.962 (0.122)***
Cost-Benefit Analysis	1.019 (0.119)***
Program Evaluation	1.312 (0.162)***